What they are
The AAD lists four older systemic medicines that may still be preferred for some patients with atopic dermatitis: azathioprine, cyclosporine, methotrexate and mycophenolate mofetil. Cyclosporine has a guide of its own here, because it is used differently from the others — typically for shorter stretches.
All of these suppress the immune system broadly, rather than targeting one signal the way a biologic does. That is the central fact about them, and it explains both their strengths and their costs.
Why they're still chosen
- Availability and cost. They are inexpensive and widely available in a way the newer options often are not, and in many situations that is the difference between being treated and waiting.
- Decades of experience. Their behaviour over long periods is very well characterised — something no medicine approved in the last few years can claim yet.
- Other conditions. If you have another condition that one of these also treats, one medicine doing two jobs can be the sensible answer.
- What's been tried. Insurance and clinical pathways often place them before a biologic. See prior authorization and appeals.
The trade-off, stated plainly. Broad immune suppression asks more of you than a targeted treatment does — blood tests on a schedule, attention to infections, and interactions to keep track of. That is a real cost and it is worth naming, not glossing. It is also a cost a great many people carry successfully for years, with skin they can live in. Neither half of that sentence should be left out.
The monitoring is the point, not the paperwork
Blood tests on these medicines are not a formality. They are how problems get caught while they are still small, which is precisely why long-term use is possible at all. If the schedule is inconvenient, say so and ask what can be arranged — skipping it quietly is the one option that isn't on the table.
What tests, how often, and what would change the plan are all questions with specific answers. Ask for them.
Questions worth asking
- "Why this one for me, rather than a biologic or a JAK inhibitor?"
- "Is this a bridge to something else, or the plan?"
- "What monitoring, how often, and for how long?"
- "What do I do if I catch something while I'm on it?"
- "What interacts with this — including anything I buy myself?"
If the answer to the first one is "because your insurance requires it first", that is worth knowing too — it's a different conversation, and one that sometimes has a route through it.
Show the year, not the day
Systemic treatment decisions turn on what happened over months: how often it flared, how much treatment it took, how many nights were lost. Ollowen keeps that record as you go, so it exists when someone finally asks for it.
Opening soonFree for 30 days · your data stays on your device
Sources
- American Academy of Dermatology. Atopic dermatitis: diagnosis and treatment.
- American Academy of Dermatology. Atopic dermatitis clinical guidelines (phototherapy and systemic agents, 2023).
- National Eczema Society. Treatments for eczema.
More Ollowen guides: see all →